Prognostic and predictive factors in patients treated with ramucirumab (RAM) with advanced hepatocellular carcinoma (aHCC) and elevated alpha-fetoprotein (AFP): Results from two phase III trials.

被引：0

作者：

Llovet, Josep M.

Singal, Amit G.

Villanueva, Augusto

Finn, Richard S.

Kudo, Masatoshi

Galle, Peter R.

Wang, Chunxiao

Widau, Ryan C.

Gugel, Elena Gonzalez

Zhu, Andrew X.

机构：

[1] Icahn Sch Med Mt Sinai, Div Liver Dis, Tisch Canc Inst, New York, NY 10029 USA

[2] UT Southwestern Med Ctr, Dept Internal Med, Dallas, TX USA

[3] Icahn Sch Med Mt Sina, Dept Med, Div Liver Dis, Mt Sinai, NY USA

[4] Univ Calif Los Angeles, Div Hematol Oncol, Los Angeles, CA USA

[5] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan

[6] Mainz Univ, Dept Internal Med, Med Ctr, Mainz, Germany

[7] Eli Lilly & Co, Indianapolis, IN 46285 USA

[8] Eli Lilly, Indianapolis, IN USA

[9] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.4146

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4146

引用

页数：2